Which molecular features must a CoA report to distinguish the two analogues?
Semaglutide is a 31-residue GLP-1(7–37) analogue. Relative to native GLP-1 it incorporates 2-aminoisobutyric acid (Aib) at position 8 and arginine at position 34, and lysine 26 is acylated through a γ-glutamyl spacer to an octadecanedioic (C18) fatty diacid. Tirzepatide, described in discovery literature as LY3298176, is a 39-residue linear peptide classified as a dual GIP and GLP-1 receptor agonist, with an eicosanedioic (C20) diacid attached through a γ-glutamyl–AEEA–AEEA linker (PMID:30473097; PMID:32730231). Receptor-class language used in characterisation papers is a pharmacological label; it is not a substitute for mass and sequence evidence (PMID:32396843; PMID:36050763).
A CoA that states only an incretin analogue at HPLC >=98% does not identify which backbone or which fatty-acid chain is present. Laboratories should require the amino-acid sequence including Aib and the acylated lysine; an explicit linker and fatty-acid description; theoretical monoisotopic and average mass; molecular formula; and counter-ion identity, typically trifluoroacetate or acetate after preparative HPLC.
Approximate average masses for intact-mass matching are about 4113.6 Da for semaglutide (C187H291N45O59) and about 4813.5 Da for tirzepatide (C225H348N48O68). That gap of roughly 700 Da is resolved by deconvoluted electrospray data, not by a diode-array purity percentage. Lots that lack a sequence block, or that show a mass inconsistent with the declared modification, should not be used to validate methods. The batch number must link the sequence claim to the chromatogram and mass spectrum of the same filling lot.
How should reversed-phase HPLC methods be set up for these acylated peptides?
Both peptides are strongly retained on C18 silica because the fatty-acid chain dominates hydrophobic interaction. Tirzepatide’s longer backbone and C20 diacid often increase retention relative to semaglutide under the same ion-pair gradient, but elution order is method-dependent and must be confirmed with reference materials. The two analytes should therefore be treated as separate system-suitability problems.
For research quality-control work, wide-pore (300 Å) C18 or C4 columns (2.1–4.6 mm internal diameter, 150–250 mm length, 3–5 µm particles) accommodate hydrodynamic size and reduce silanol effects. Water/acetonitrile with 0.05–0.1% trifluoroacetic acid (TFA) is common for purity profiling; formic acid is preferable when the same run is split to mass spectrometry, because TFA suppresses electrospray ionisation. A shallow acetonitrile ramp through the acylated elution window is required: a steep gradient merges des-acyl, mono-oxidised and incompletely conjugated species into the main peak. Detection at 214–220 nm records peptide-bond absorbance; 280 nm is a secondary trace where tryptophan is present. Diode-array peak-purity indices are supportive only, because related substances are often spectrally similar.
System suitability should include tailing factor, plate count, and resolution to the nearest specified related substance, with blanks and a sensitivity solution in the injection sequence. Report area-normalised chromatographic purity with stated peak-threshold and integration rules. Amphipathic peptides adsorb to vials and filters; use low-adsorption vials, a defined diluent and a documented hold time. Retention time alone must not identify semaglutide versus tirzepatide unless relative retention has been qualified against both references on that column lot and gradient. HPLC remains the purity and related-substance tool; mass spectrometry remains the identity tool.
What HPLC-MS data distinguish semaglutide vs tirzepatide on a research CoA?
Electrospray ionisation of these peptides produces a multiply charged envelope, typically in the 3+ to 7+ region. Identity confirmation records that envelope, deconvolutes it to a zero-charge mass, and compares the result with the theoretical mass of the declared sequence plus modification, within a pre-defined acceptance window. High-resolution instruments often use a 0.5–1.0 Da or a ppm limit stated in the standard operating procedure; unit-resolution instruments require a wider window plus isotopic or orthogonal evidence.
A deconvoluted mass near 4114 Da supports semaglutide; a mass near 4814 Da supports tirzepatide. A result matching neither value indicates a different analogue, an adduct mis-assignment, a truncation, or a missing or extra acyl group. Frequent interpretation errors include treating a sodium or potassium adduct as the free molecule, ignoring the counter-ion when calculating theoretical mass, and comparing a monoisotopic theoretical value with an average-mass experimental value.
Where tandem mass spectrometry is available, fragment ions covering the N-terminal Aib region, the acylated lysine and the C-terminus increase confidence. Reporter fragments from the fatty-acid–linker cassette help confirm that the hydrophobic modification is present. Full sequence coverage is uncommon from a single intact-MS/MS experiment on 4–5 kDa acylated peptides, so the file should state which regions were observed. The CoA should attach the annotated deconvoluted spectrum, acquisition mode, calibration reference and the numerical acceptance criterion. MALDI-TOF can corroborate electrospray results if adduct patterns and calibration drift are controlled; disagreement larger than the combined uncertainty should trigger re-preparation. For Australian research lots, the HPLC chromatogram and the MS identity result must share the same batch number.
Which related-substance classes should be profiled for each sequence?
Related substances arise from synthesis, purification and storage. Because the backbones and linkers differ, impurity names on a semaglutide CoA are not transferable to a tirzepatide lot.
Incomplete acylation or linker truncation yields lower-mass, usually earlier-eluting species. For tirzepatide, loss of an AEEA unit or the C20 diacid is a specific process risk; for semaglutide, a missing C18 diacid or γ-glutamyl spacer is the corresponding risk. Solid-phase synthesis also generates deletion and truncation sequences, diastereomers, and aspartimide-related peaks near aspartic acid residues. Tryptophan oxidation appears as +16 Da species on intact-mass records. Deamidation of asparagine or glutamine is often poorly resolved in TFA ion-pair HPLC and is better observed by peptide mapping or by charge-variant ion-exchange chromatography. Residual protecting groups and deletion of Aib change mass by defined increments. Aggregates and multimers are better addressed by size-exclusion chromatography than by reversed-phase HPLC.
Acceptance criteria belong in the laboratory specification before testing begins. A research specification may require chromatographic purity at or above a stated area-percent, any unspecified impurity below a stated threshold, and intact mass within the identity window. Forced-degradation studies using acid, base, oxidation, light and thermal stress of the solid help laboratories recognise which peaks are degradants versus process impurities; they are peak-tracking tools, not shelf-life claims. If HPLC purity is high but net peptide content by amino-acid analysis or nitrogen determination is substantially lower, counter-ion, residual solvent and water usually explain the gap. That gap is a documentation issue, not evidence that a different peptide is present.
What lot documentation should Australian laboratories require before accepting either analogue?
A research CoA should allow a receiving laboratory in Australia to reconstruct identity, purity, content and traceability without contacting the supplier. Minimum fields include: product name and full sequence with modifications; batch or lot number and documentation date; appearance of the lyophilised solid; HPLC purity with method identifier, chromatogram and integration parameters; intact mass (experimental and theoretical) with spectrum and instrument identifier; net peptide content and the method used; counter-ion identity and, where measured, residual trifluoroacetate; water by Karl Fischer; residual solvents if claimed; and milligrams of peptide per vial, stated separately from milligrams of lyophilisate.
Lot traceability matters when several vials share a bulk lot. The batch report should state whether each vial is from the same filling lot and whether the attached HPLC and mass-spectrometry files belong to that lot. A shared CoA is acceptable for multi-vial orders only if the sampling plan is described. Australian procurement should favour local stock and tracked dispatch so that the order number, consignment identifier and received packaging condition can be filed with the CoA. Lots should be rejected when the CoA sequence does not match the purchase order, when the measured mass does not match the sequence, or when chromatograms appear recycled across supposedly different lots.
Regulatory framing remains research-only. Documentation should not mimic a medicine information leaflet. The receiving organisation applies its own quality system, including incoming inspection, unique sample identifiers and retained raw data. ClaraScience’s research-supply model is built around batch documentation and lot-linked spectra rather than unsubstantiated catalogue claims.
How should laboratories assemble an orthogonal identity file for both analogues?
When a project holds both peptides as distinct reference analytes, open two identity files rather than one combined incretin-analogue file. A practical orthogonal set comprises: reversed-phase HPLC purity and relative retention against each laboratory reference; high-resolution intact mass; optional targeted tandem MS of diagnostic fragments; counter-ion assay by ion chromatography or fluorine-19 NMR for trifluoroacetate; Karl Fischer water; amino-acid analysis or nitrogen content for net peptide; appearance and solubility in the documented sample-preparation diluent; charge-variant ion-exchange chromatography if deamidation is in scope; and size-exclusion chromatography if aggregation is in scope.
Comparison tables should list theoretical mass, observed mass, mass delta, HPLC purity, net content, counter-ion, water and document revision. Do not collapse the two analogues into a single specification, because masses, retention and impurity catalogues differ. If a supplier cannot provide a chromatogram and a deconvoluted mass for the same lot, perform incoming identity testing before the material is used to qualify methods. Independent confirmation is important where catalogue names have been widely copied in grey-market synthesis. Wrong fatty-acid chain length, mixed lots and sequence errors are identity failures, not purity failures.
Retain raw chromatograms and spectra for the same period as other analytical records. Filenames should include analogue name, lot, technique and date so that semaglutide and tirzepatide files cannot be interchanged. Incoming inspection records should cross-reference the purchase order, the CoA lot number and the instrument data file names. This workflow is quality-system practice for research materials; it does not establish suitability for any biological protocol.
Order Tirzepatide or Semaglutide with documentation
This guide focused on how laboratories verify identity and purity for Tirzepatide and Semaglutide. If that evaluation is complete, you can move from documentation review into research-grade stock held in Australian warehouses, with Express tracked dispatch and a COA tied to each order.
Jump straight to the product card on the ClaraScience shop to add research-grade stock, or open wholesale access if you restock at volume.
Frequently asked questions
Can HPLC purity alone distinguish semaglutide from tirzepatide?
No. Area-percent purity does not encode backbone length or fatty-acid chain length. A mislabelled analogue can still meet a 98% HPLC figure on a short gradient. Intact mass (near 4114 Da versus near 4814 Da), together with a documented sequence and linker description on the same lot, is required before the material is accepted as either analogue.
What CoA fields are essential for Australian research lots of either analogue?
Sequence with modifications, lot number, HPLC chromatogram and purity method, deconvoluted intact mass with the theoretical value, net peptide content, counter-ion, water, and milligrams of peptide per vial. The chromatogram and mass spectrum must belong to the same filling lot. Local Australian stock and tracked dispatch support chain-of-custody filing.
Why does fatty-acid acylation matter for identity testing?
The C18 diacid–γ-Glu cassette on semaglutide and the C20 diacid–γ-Glu–AEEA–AEEA cassette on tirzepatide change both intact mass and reversed-phase retention. Des-acyl or partial-linker species are different chemical entities and should be reported as related substances, not hidden inside a steep-gradient main peak.
Should the two analogues share one HPLC specification?
No. Theoretical mass, retention and the impurity catalogue differ. Separate system-suitability criteria, identity mass windows and related-substance lists should be written into the laboratory standard operating procedure before either analogue is used as a reference for research quality-control work.
How should multi-vial orders of these analogues be documented?
The batch report should state whether vials share a filling lot and whether attached HPLC and mass-spectrometry files belong to that lot. Incoming inspection should cross-reference the purchase order, the CoA lot number and the instrument data-file names.
What is the role of HPLC versus mass spectrometry in this comparison?
Use HPLC for area-percent purity and related-substance profiling, and use deconvoluted intact mass—optionally with diagnostic fragment ions—for identity. Retention time is not an identity test unless both laboratory references have been qualified on that exact method.
References
- PMID:30473097 — LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept — Mol Metab — 2018
- PMID:32730231 — Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist — JCI Insight — 2020
- PMID:32396843 — How May GIP Enhance the Therapeutic Efficacy of GLP-1? — Trends Endocrinol Metab — 2020
- PMID:36050763 — Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction — Cardiovasc Diabetol — 2022
Research use only
This article is provided for laboratory research and educational purposes only. Products referenced are not for human or veterinary use. ClaraScience makes no therapeutic, medical, or efficacy claims, and nothing here constitutes medical advice.
